background image for GxP Lifeline
GxP Lifeline
  • Life science professional working on 21 cfr part 11 compliance requirements.

    A Complete 21 CFR Part 11 Compliance Checklist for Quality Managers

    Compliance with 21 CFR Part 11 is a big deal for life sciences companies. Failure to meet Part 11 requirements can result in serious consequences like product recalls and legal actions. Make sure all your regulatory bases are covered with this 21 CFR Part 11 compliance checklist.

    Full story
  • 2022-bl-data-integrity-strategy_132x132

    How to Avoid Warning Letters for Data Integrity Nonconformances

    According to the U.S. Food and Drug Administration’s (FDA) guidance on data integrity, all data for regulated products must be complete, reliable, accurate, and consistent. Learn data management best practices to help ensure compliance with the stringent data integrity regulations.

    Full story
  • 2021-bl-cfr-part-11_132x132

    21 CFR Part 11: Nearly Three Decades of Shaping FDA Compliance in Life Sciences

    The U.S. Food and Drug Administration’s (FDA) 21 CFR Part 11 guidance made electronic records and signatures as valid as paper records and handwritten signatures. The guidance changed the dynamic of data and records management by advocating modernized technology in the life sciences industry.

    Full story
  • 2021-bl-compliance-checklist_132x132

    Q&A: A Risk-Based Approach to Compliant Audit Trails

    More regulated companies have transitioned to maintaining records and submitting information electronically. This involves tight data and records management and audit trails. In this article, Seyed Khorashahi, executive vice president of medical devices and CTO at Regulatory Compliance Associates (RCA) Inc., shares valuable insight on the anatomy of an audit trail and advises companies on how to comply with this critical component of 21 CFR Part 11.

    Full story
  • 2020-bl-gxp-lifeline-template_132x132

    Simplifying Part 11

    21 CFR Part 11 went into effect more than 20 years ago, and it remains a widely discussed regulation.

    Full story
  • 2019-bl-thumb-purpose-bulit-manufacturing-systems

    FDA Predicate Rules: The Key to 21 CFR Part 11 Compliance for Life Sciences Quality Managers

    FDA 21 CFR Part 11 does not invalidate the predicate rules that were established for paper-based document management systems, it simply builds upon and reinforces those existing rules in digital platforms. Learn about the symbiotic nature of Part 11 and FDA predicate rules and discover how an awareness of their relationship is fundamental to easing compliance burdens.

    Full story
  • MasterControl Logo

    The Challenges of Cloud Compliance in a Regulated Environment

    Life sciences companies are migrating the cloud. To be successful with cloud compliance in a regulated environment, it’s important to understand the key challenges and know how to address them. While cloud host providers offer security features, it is your organization’s responsibility to confirm the provider is compliant.

    Full story
  • 2020-bl-thumb-data-integrity-and-21-cfr-part-11

    How Harmonizing 21 CFR Part 11 and Data Integrity Delivers Higher Quality Products

    Complying with the many record and data management requirements for 21 CFR Part 11 and data integrity can be daunting. In this article, Matt Brawner, data integrity subject matter expert (SME) at Sequence Inc., explains how companies can integrate Part 11 and data integrity processes to accelerate pathways to approval and deliver higher quality products to market.

    Full story
  • 2018-bl-thumb-regulatory-barriers-for-biotech-medtech-startups-europe

    Regulatory Barriers to Innovation for Startups

    France and Europe are witnessing an explosion of life science innovation from new startups. But what separates the winners from the losers? Learn how to successfully overcome regulatory barriers and get your product to market quicker.

    Full story
  • 2018-bl-thumb-eus-gdpr

    GDPR Deadline Approaches: What Is Expected for Compliance?

    First the bad news. As long as health care-related data remains a valuable commodity, security breaches and data theft will persist. The good news is global regulatory agencies are ramping up their cybersecurity measures in an effort to restore relevance to the “protection” component of protected health information (PHI).

    Full story
[ { "key": "fid#1", "value": ["GxP Lifeline Blog"] } ]